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ORIGINAL ARTICLE
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ABSTRACT
Background: Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of
patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received
standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited.
The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas.
Patients and methods: A retrospective study of patients with advanced vascular sarcomas, including
angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazo-
panib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III
clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response
was assessed according to RECIST 1.1. and survival analysis was performed.
Results: Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS,
respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS sub-
types, respectively. There was no significant difference in response rate between cutaneous and non-
cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median pro-
gression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three
months (95% CI 2.1–4.4) and 9.9 months (95% CI 6.5–11.3) in AS, respectively.
Conclusion: The activity of pazopanib in AS is comparable to its reported activity in other STS sub-
types. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/
non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of
further evaluation.
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Soft tissue sarcomas (STS) represent a highly heterogeneous
group of tumors with differing underlying biology, clinical
behavior and response to systemic therapy [1]. Within this
family of tumors, vascular sarcomas such as angiosarcoma
(AS), epithelioid hemangioendothelioma (HE) and intimal sar-
coma (IS), account for about 2–3% of adult STS [2]. The
worldwide age-standardized incidence rate of AS is approxi-
mately 0.1/100000/year [3].
There are few prospective data on the utility of systemic
therapy in vascular sarcomas. The majority of prospective tri-
als evaluating systemic therapies in sarcomas have generally
included all or many STS subtypes in a one size fits all
approach. Consequently, the number of patients with vascu-
lar sarcomas in such trials is low. Based on retrospective
data, standard first- and second-line therapy for AS include
doxorubicin- and taxane-based regimens. Furthermore, there
have been a number of phase II trials in AS. The phase II
AngioTax trial reported a response rate to weekly paclitaxel
of 20% with a disease stabilization rate of 75% after three
months and 24% after six months [4]. First-line single-agent
doxorubicin and weekly paclitaxel seem to have similar effi-
cacy in metastatic AS [5,6]. First-line anthracycline-based
chemotherapy was associated with a partial response rate of
25% and a median progression-free survival (PFS) of 4.9
months [7].
Vascular sarcomas are known to express pro-angiogenic
growth factors such as vascular endothelial growth factor
(VEGF) [8]. Therefore, the evaluation of vascular-targeted
agents in vascular tumors such as AS, HE and IS is of particu-
lar interest. Accordingly, bevacizumab was investigated for
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the treatment of AS and HE confirming promising efficacy
results represented by a median PFS of 12 and 52.7 weeks,
respectively [9]. In two phase II trials by Maki and Ray-
Coquard and colleagues, a median PFS in the range of
1.8–3.8 months, respectively, was reported for sorafenib in
AS [10,11].
Pazopanib is a tyrosine kinase inhibitor targeting several
factors including VEGFR1-3 and PDGFR and has been
approved by the European Medicines Agency (EMA) for the
treatment of patients with advanced non-adipocytic STS who
have previously been treated with anthracycline- or ifosfa-
mide-based chemotherapy [12]. There are few published data
on the efficacy of pazopanib in vascular sarcomas [13]. Due
to the small number of patients with vascular sarcomas
included in the EORTC STS phase II and III trials, a meaningful
evaluation of its activity in these subtypes is not possible
[14,15]. There have been case reports and small case series
documenting the potential efficacy of pazopanib in vascular
sarcomas [16–19]. In addition, pazopanib is the only tyrosine
kinase inhibitor approved for non-adipocytic STS together
with imatinib in DFSP, and therefore further evaluation of
this agent in vascular sarcomas has an added value.
Consequently, the aim of this study was to document the
efficacy of pazopanib in a cohort of patients with advanced
vascular sarcomas treated at a number of EORTC centers and
within the two EORTC trials, in order to provide a benchmark
for further studies and clinical practice.
Material and methods
Patient population and data collection
Ethical approval was obtained according to local and national
regulations. A retrospective search of patients with advanced
vascular sarcomas treated with pazopanib at EORTC-STBSG
centers was performed. In addition, patients with vascular
sarcomas treated within the phase II and III EORTC pazopanib
trials (62043/62072) were identified. Patients were included
in the analysis regardless of treatment line. In some patients
pazopanib was given in the first-line setting as pazopanib is
reimbursed in several countries as first-line therapy if patients
are not suitable for treatment with anthracyclines. Pazopanib
was administered according to standard ESMO Guidelines
and local institutional policy. Clinical, pathological and out-
come data were obtained from the individual patient records
and from the EORTC database for the patients treated within
trials. The diagnosis was confirmed in all cases by an experi-
enced STS pathologist. All patients (but one) were confirmed
to have progressive disease before treatment start.
Endpoints
The study endpoints were response rate to pazopanib, PFS
and overall survival (OS). The objective response rate was
assessed per RECIST 1.1. The disease control rate was defined
as the sum of complete response, partial response and stable
disease. PFS was defined from the date of commencing pazo-
panib to the first documentation of progression or death. For
data obtained from the EORTC trials, the definition of
progression was according to the radiological assessment of
the principal investigator; in the absence of radiologically
documented progression, clinical progression was also taken
into account.
OS was calculated from the starting date of pazopanib
administration to the date of death. Patients alive at the time
of analysis were censored at the date of last follow-up.
For patients with AS treated with pazopanib, the outcome of
those with cutaneous and non-cutaneous types was
compared, and likewise for radiation-associated and
non-radiation-associated.
Statistical analysis
Descriptive summary statistics of patients, tumor and treat-
ment characteristics, and response to treatment are provided
overall as well as stratified by the histologic subtypes of vas-
cular sarcoma (AS, HE and IS). Furthermore, the response rate
of AS was determined by origin of the primary tumor (cuta-
neous/non-cutaneous) and by association with radiation ther-
apy (Yes, No), and tested for association with these
covariates using a v2-test.
Survival curves for PFS and OS were generated using the
Kaplan–Meier method for the different histologic subtypes.
Estimates of medians and corresponding 95% confidence
intervals (CI) are reported.
Results
Patient and tumor characteristics
A total of 52 patients were identified, including nine patients
from the EORTC phase II and III trials (62043 and 62072).
Sixteen institutions in eight countries contributed to this ana-
lysis. Baseline patient and tumor characteristics are summar-
ized in Table 1. Among the vascular sarcoma patients
included, 40 (76.9%) had AS, 10 (19.2%) had HE and two
(3.8%) had IS. Focusing on the AS cohort the overall median
age at diagnosis was 62.4 years (range 30–83.4 years). A total
Table 1. Patient and tumor characteristics of vascular sarcomas.
Angiosarcoma
N¼ 40 N (%)
Epithelioid
hemangioendothelioma
N¼ 10 N (%)
Intimal sarcoma
N¼ 2 N (%)
Median age (years) 62.4 47.2 67.2
Gender
Female 15 (37.5%) 4 (40%) 1 (50%)
Male 25 (62.5%) 6 (60%) 1 (50%)
Disease stage
Locally advanced 8 (20%) 2 (20%) 1 (50%)
Metastatic 32 (80%) 8 (80%) 1 (50%)
Site of primary tumor
Breast 15 (37.5%) 0 (0%) 0 (0%)
Scalp/Head 6 (15%) 1 (10%) 0 (0%)
Abdomen 8 (20%) 4 (40%) 0 (0%)
Thorax 7 (17.5%) 4 (40%) 1 (50%)
Extremity 4 (10%) 1 (10%) 1 (50%)
Localization
Skin 15 (37.5%) 0 (0%) 0 (0%)
Non-skin 24 (60%) 10 (100%) 2 (100%)
Unknown 1 (2.5%) 0 (0%) 0 (0%)
Radiation-induced
Yes 14 (35%) 0 (0%) 0 (0%)
No 26 (65%) 10 (100%) 2 (100%)
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of 62.5% of patients were male. The most common primary
tumor site was breast (n¼ 15) and scalp (n¼ 6). Additionally,
AS was diagnosed in the abdomen (adrenal gland, liver, geni-
tourinary) (n¼ 8), chest (including pulmonary artery) (n¼ 7)
and extremities (n¼ 4). Twenty-four patients (60%) had non-
cutaneous AS and 14 patients (35%) had radiation-associated
AS.
Treatment details before and after pazopanib
In five patients (9.6%) pazopanib was given in the first-line
setting (Table 2). The most commonly administered previous
treatments were paclitaxel (54.5%, n¼ 25) and doxorubicin
(43.5%, n¼ 20). The details of other treatments administered
are displayed in Supplementary Table 1 (available online at
http://www.informahealthcare.com).
Of the patients on follow-up at the time of analysis, 21
(48.8%) received no additional therapy, 18 (41.9%) received
one further line of therapy and four patients (9.3%) received
two further lines of therapy (Table 2). The most commonly
administered drugs following progressive disease on pazopa-
nib were gemcitabine (21.1%, n¼ 8) and paclitaxel (18.4%,
n¼ 7). Details for the other therapies administered are pro-
vided in Supplementary Table 1.
Clinical outcome and prognostic factors
All patients (but one) were confirmed to have progressive
disease before treatment start. The median follow-up was
15.9 months (95% CI 12.8–38.2), and it was not possible to
obtain response data for three patients (5.8%). Overall, 26
patients (50%) experienced progressive disease, 11 patients
(21.2%) had stable disease, 11 patients (21.2%) a partial
response and one patient (1.9%) had a complete response
(Table 3), leading to a disease control rate for the total group
of 44.3%.
In the AS cohort, the rate of partial response and stable
disease was 20% and 17.5%, respectively, representing a clin-
ical benefit rate of 37.5% (Table 3). The response rate was
similar in cutaneous and non-cutaneous AS, 26.7% and 16.7%
(p¼ 0.54), respectively. Furthermore, the response rate was
28.6% in the radiation-associated cohort and 15.4% in the
non-radiation-associated AS cohort (p = 0.39), respectively
(Table 4).
In the cohort of patients with HE, the clinical benefit rate
was 60% of which 67% (i.e. 4 of 6) experienced disease sta-
bilization as the best response. Of note, both patients with IS
had a partial response (Table 3).
The median PFS was three months (95% CI 2.1–4.4) in the
AS cohort and 26.3 months (0.2–N) in the HE cohort, respect-
ively (Figure 1). The median OS from date of treatment start
was 9.9 months (95% CI 6.5–11.3) and 26.3 months (95% CI
0.5–N) for AS and HE, respectively.
Discussion
STS represent a group of rare and heterogeneous tumors of
mesenchymal origin, with each subtype having differing
underlying biology, clinical behavior and response to sys-
temic therapy. In view of the rarity of these tumors they
have often been grouped together for the purpose of clinical
trials, and consequently the results of such trials have often
been difficult to interpret with regard to the benefit of an
individual drug or schedule in a specific subtype. We aimed
to get more information on a couple of vascular sarcomas in
patients treated with pazopanib within the first clinical trials
and in daily clinical practice after registration.
Our study documented a disease control rate of 40% and
a median PFS of three months for AS patients treated with
pazopanib. These results are consistent with the phase II
data of sorafenib in AS [10]. In the PALETTE trial, the median
PFS of 4.6 months was slightly higher in the STS group over-
all [15]. Up-regulation of angiogenic growth factors is
thought to play a major role in the pathomechanism of sev-
eral tumors, including ASs. In the latter Itakura et al. report
on an immunohistochemical expression of certain VEGFs and
their receptors in over 90% of patients [20]. Therefore, one
would expect a higher response rate to angiogenic drugs in
Table 2. Treatment details before and after pazopanib.
Angiosarcoma
(N¼ 40)
Epithelioid
hemangioen-
dothelioma
(N¼ 10)
Intimal
sarcoma
(N¼ 2)
Total
(N¼ 52)
N (%) N (%) N (%) N (%)
Number of previous
treatment lines
0 4 (10.0) 1 (10.0) 0 (0.0) 5 (9.6)
1 14 (35.0) 2 (20.0) 2 (100.0) 18 (34.6)
2 12 (30.0) 5 (50.0) 0 (0.0) 17 (32.7)
>2 10 (25) 2 (20.0) 0 (0.0) 12 (23.1)
Number of treatment
lines after pazopanib
(N¼ 36) (N¼ 5) (N¼ 2) (N¼ 43)
N (%) N (%) N (%) N (%)
0 18 (50.0) 3 (60.0) 0 (0.0) 21 (48.8)
1 15 (41.7) 2 (40.0) 1 (50.0) 18 (41.9)
2 3 (8.3) 0 (0.0) 1 (50.0) 4 (9.3)
Table 3. Best response to pazopanib.
Angiosarcoma
(N¼ 40)
Epithelioid
hemangioendothelioma
(N¼ 10)
Intimal
sarcoma
(N¼ 2)
Total
(N¼ 52)
N (%) N (%) N (%) N (%)
Best response
Complete response 0 (0.0) 1 (10.0) 0 (0.0) 1 (1.9)
Partial response 8 (20.0) 1 (10.0) 2 (100.0) 11 (21.2)
Stable disease 7 (17.5) 4 (40.0) 0 (0.0) 11 (21.2)
Progressive disease 23 (57.5) 3 (30.0) 0 (0.0) 26 (50.0)
Unknown 2 (5.0) 1 (10.0) 0 (0.0) 3 (5.8)
Table 4. Response rate (CR and PR) according to RECIST 1.1. For angiosarcoma
patients.
Patients Response rate Chi-square test
N = 40 N (%) p-value
Localization of first tumor
Skin 15 4 (26.7%)
Non-skin 24 4 (16.7%) 0.54
Missing 1 0 (0.0%)
Radiation-associated
Yes 14 4 (28.6%)
No 26 4 (15.4%) 0.39
Total 40 8 (20%)
CR: complete response; PR: partial response.
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AS patients when compared to other STS. However, our
results do not support this assumption. It should be noted
that the patients in our cohort were heavily pretreated, with
25% having received more than two lines of systemic therapy
prior to commencing pazopanib. The most commonly
employed chemotherapy drugs were paclitaxel, gemcitabine
and liposomal doxorubicin.
Several retrospective studies suggest that cutaneous AS is
a relatively chemosensitive subtype, particularly to paclitaxel,
but data on targeted agents are lacking [21]. However, in our
cohort no significant difference in the efficacy of pazopanib
was observed between patients with primary cutaneous and
non-cutaneous primary tumor sites. Radiation-associated AS
is known to express several angiogenic biomarkers (i.e. VEGF)
supporting the rationale for angiogenesis inhibitors in
patients with these tumors [8]. However, no significant differ-
ence in response rate was observed between radiation-asso-
ciated and non-radiation-associated AS, but the number of
patients is in fact too small to draw firm conclusions.
HE has a spectrum of behavior from indolent to very
aggressive. Overexpression of vascular growth factor recep-
tors (VEGF, VEGFR2, and VEGFR3) has been observed in pul-
monary HE samples [22]. Given its vascular origin,
angiogenesis inhibition may be a reasonable therapeutic
approach for the management of this subtype. Interferon-2,
which has some anti-angiogenic activity, has been reported
to result in responses in some case reports [23]. In the trial
by Agulnik et al. the efficacy of bevacizumab was assessed in
HE and AS. Seven patients with HE were included; two had a
partial response and four had stable disease [9]. A phase II
trial of sorafenib by the French Sarcoma Group included 15
patients with HE; two patients had a partial response and
five SD [24]. Our results are consistent with the French
Sarcoma Group trial, and demonstrate that pazopanib can
result in RECIST responses in some patients with HE.
Additionally, our survival data are consistent with the
reported mean survival of approximately 4.6 years including
a broad range from six months to 24 years [25]. However, all
of these observations are limited by the small patient num-
bers due to the rarity of this disease.
There are few published data regarding systemic therapy
in IS, although patients are often treated with anthracyclines
and ifosfamide [26]. To our knowledge no data of antiangio-
genic therapy is available in this subtype. In view of both
patients achieving a partial response to pazopanib further
evaluation is warranted in this subtype.
Our study is limited by its retrospective nature and small
sample size. However, to our knowledge, this report repre-
sents the largest published series of patients with advanced
vascular sarcomas treated with pazopanib. Our study sug-
gests that pazopanib has activity in AS, but the responses
observed in patients with HE and IS warrant further investi-
gation. Investigating potential predictive markers on a
molecular level for suggested differences in treatment sensi-
tivity between AS, HE or IS, respectively, or between pazopa-
nib responders and non-responders in the AS cohort would
be of major interest.
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